Clinical findings with the oral contraceptive combinationethinylestradiol/dienogest in poland

S Golbs, Reiner Domhardt, S Radowicky, Zbigniew Kaluzny, K H Wisser, Thomas Zimmermann
In: Methods and Findings in Experimental and Clinical Pharmacology · 2002 · vol. 24(9) , pp. 585 · doi:10.1358/mf.2002.24.9.802311 · PMID:12616705 · W2413082455
article OA: closed CC0 ⤵ 11 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This phase III trial found that ethinylestradiol/dienogest provided reliable ovulation inhibition with no pregnancies and good cycle control, improving androgen-related conditions while causing mild, transient side effects.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The efficacy and safety of the low dose monophasic oral contraceptive (OC) combination containing 30 micrograms of ethinylestradiol (EE) and 2.0 mg of dienogest (DNG) (EE/DNG) was evaluated in a prospective, open-label, multicenter, uncontrolled, phase III trial. The trial was carried out in five hospitals in Poland, and included 431 healthy women (aged 18-35 years), over 12 cycles, with a total of 4608 cycles. EE/DNG provided reliable ovulation inhibition. No women became pregnant during the trial. The unadjusted Pearl index was 0. EE/DNG provided good cycle control and reduced the incidence of intermenstrual bleedings, the intensity of menstrual bleeding and frequency of dysmenorrhea. Due to the antiandrogenic properties of the progestogen component DNG, EE/DNG improved androgen-related conditions, such as skin blemishes, hair greasiness and acne vulgaris. Of 50 women with acne, 80% improved after the 6th cycle and 1 was healed. After 12 cycles, 54% were improved and 37% were healed. Breast tenderness and gastric complaints were the most frequent of the common complaints due to treatment with EE/DNG. The frequency of all complaints decreased steadily over time. Only 5.6% of subjects discontinued due to adverse reactions. No thrombophlebitic events were noticed.

My notes (saved in your browser only)

Condition tags

dysmenorrhea

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

Cited by (10)

Source provenance

openalex
last seen: 2026-05-11T04:20:12.799902+00:00
unpaywall
last seen: 2026-10-05T06:32:29.880811+00:00
License: CC0 · commercial use OK